These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36963900)

  • 1. Oral microbiota and liver diseases.
    Elghannam MT; Hassanien MH; Ameen YA; Turky EA; Elattar GM; ElRay AA; Eltalkawy MD
    Clin Nutr ESPEN; 2023 Apr; 54():68-72. PubMed ID: 36963900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
    J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
    Wang T; Ishikawa T; Sasaki M; Chiba T
    Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Gut Microbiome and Hepatocellular Carcinoma.
    Akkız H
    J Gastrointest Cancer; 2021 Dec; 52(4):1314-1319. PubMed ID: 34870783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
    Ezzaidi N; Zhang X; Coker OO; Yu J
    Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut microbiota - A vehicle for the prevention and treatment of hepatocellular carcinoma.
    Beyoğlu D; Idle JR
    Biochem Pharmacol; 2022 Oct; 204():115225. PubMed ID: 35998677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
    Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
    BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiota, cirrhosis, and the emerging oral-gut-liver axis.
    Acharya C; Sahingur SE; Bajaj JS
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma.
    Rao BC; Lou JM; Wang WJ; Li A; Cui GY; Yu ZJ; Ren ZG
    Hepatobiliary Pancreat Dis Int; 2020 Apr; 19(2):109-115. PubMed ID: 32037278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
    Das BK
    APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
    Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
    Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
    Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
    Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
    Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
    Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
    Ren Z; Li A; Jiang J; Zhou L; Yu Z; Lu H; Xie H; Chen X; Shao L; Zhang R; Xu S; Zhang H; Cui G; Chen X; Sun R; Wen H; Lerut JP; Kan Q; Li L; Zheng S
    Gut; 2019 Jun; 68(6):1014-1023. PubMed ID: 30045880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.